HNGE
HealthcareHinge Health, Inc. · Medical - Healthcare Information Services · $4B
What is Hinge Health, Inc.?
Hinge Health is a digital health company focused on musculoskeletal care — one of the most common and costly areas of employee health. Its software platform connects patients with guided programs for joint and muscle conditions, reducing the need for surgery or in-person specialist visits.
Hinge Health operates a software-based care platform targeting musculoskeletal conditions including chronic pain, acute injuries, and post-surgical rehabilitation. Employers and health plans contract with Hinge Health to offer its digital programs to their members. Patients access guided exercise therapy, health coaching, and clinical support through the platform. The company also provides administrative and operations support services to help organizations manage musculoskeletal care programs at scale.
Hinge Health was founded in 2012 and is headquartered in San Francisco, California.
- Digital musculoskeletal care platform for joint and muscle health
- Chronic pain and acute injury management programs
- Post-surgical rehabilitation support
- Employer and health plan administrative services
- Remote clinical coaching and guided exercise therapy
Is HNGE a Good Stock to Buy?
UQS Score rates HNGE as Good overall, reflecting a mixed but growth-oriented profile.
The most notable strength in Hinge Health's profile is its Growth pillar, which ranks among the strongest signals in the assessment. Valuation also registers as Good, suggesting the market's current pricing is not stretched relative to the company's stage and fundamentals.
The Quality and Moat pillars both register as Weak — indicating that profitability and competitive defensibility remain areas to watch as the company scales.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HNGE pay dividends?
No — Hinge Health, Inc. does not currently pay a dividend.
Hinge Health does not currently pay a dividend. As a growth-stage digital health company, capital is directed toward platform development, customer acquisition, and expanding its clinical capabilities rather than returning cash to shareholders. Investors drawn to HNGE are typically focused on long-term growth potential rather than income.
When does HNGE report earnings?
Hinge Health reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a recently public company, Hinge Health's quarterly results are closely watched for signs of revenue growth, improving unit economics, and progress toward profitability. The Growth pillar in UQS reflects meaningful top-line momentum, though Quality metrics indicate the path to sustained profitability is still developing.
For the most recent quarter's results and guidance, visit Hinge Health's investor relations page directly.
HNGE Price History
+14.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
HNGE Long-term Outlook
Hinge Health's fundamental outlook is shaped by a Strong Growth pillar alongside Weak Quality and Moat signals. This combination suggests the company is expanding its addressable market and revenue base, but has not yet established durable competitive advantages or consistent profitability. The Neutral Risk profile indicates the business is not facing acute financial distress, though execution risk remains elevated for a company at this stage. Valuation rated as Good implies the current price may already reflect a degree of growth optimism.
Growth drivers
- Expanding employer and health plan adoption of digital musculoskeletal programs
- Broadening platform capabilities across chronic, acute, and post-surgical care
- Secular shift toward virtual-first and value-based healthcare delivery
Key risks
- Weak Moat signals suggest limited pricing power and competitive differentiation
- Weak Quality pillar reflects ongoing pressure on margins and profitability
- Valuation leaves limited room for execution missteps given growth expectations
HNGE vs Peers
Hinge Health operates in a competitive digital and tech-enabled healthcare landscape alongside companies pursuing different angles of the same broad market.
10x Genomics focuses on genomics and spatial biology tools rather than care delivery, representing a different technology layer within the broader healthcare innovation space.
Privia Health operates a physician enablement platform, competing for employer and health plan contracts through a primary care and value-based care model rather than musculoskeletal specialization.
Heartflow applies AI-driven analysis to cardiovascular diagnostics, targeting a different clinical condition but competing for similar digital health budget allocations within health systems.
Frequently Asked Questions
What does Hinge Health do?
Hinge Health develops a digital platform for musculoskeletal care, covering chronic pain, acute injuries, and post-surgical rehabilitation. Employers and health plans offer the platform to their members as an alternative to traditional in-person specialist care. The company also provides administrative support services to help organizations manage these programs.
Does HNGE pay dividends?
No, Hinge Health does not currently pay a dividend. The company is in a growth phase and reinvests capital into its platform and market expansion. Investors in HNGE are generally seeking capital appreciation rather than income.
When does HNGE report earnings?
Hinge Health follows a standard quarterly earnings cadence for US-listed companies. For exact dates and the most recent results, check the investor relations section of Hinge Health's official website.
Is HNGE a good stock to buy?
UQS Score rates HNGE as Good overall, driven primarily by a Strong Growth pillar and a Good Valuation rating. However, Weak Quality and Moat scores indicate the company has not yet established durable profitability or a clear competitive moat. Whether that profile suits your portfolio depends on your risk tolerance and investment horizon.
Is HNGE overvalued?
The UQS Valuation pillar for HNGE is rated Good, suggesting the current market price is not significantly stretched relative to the company's growth stage. That said, growth-stage digital health companies carry inherent valuation uncertainty. The complete valuation analysis is available to UQS Pro members.
How does HNGE compare to its competitors?
Hinge Health is differentiated by its focus on musculoskeletal care delivered through a software platform, while peers like Privia Health focus on physician enablement and Heartflow targets cardiovascular diagnostics. Each addresses a different clinical niche within the broader digital health market. See the full competitor comparison in the UQS Pro view.
What is HNGE's market cap bracket?
Hinge Health is currently classified as a mid-cap company. This places it in a segment of the market that often balances growth potential with more established operations than smaller peers, though it remains subject to the volatility typical of growth-oriented healthcare companies.
Who founded Hinge Health?
Hinge Health was founded in 2012. For detailed information about the company's founders and early history, the company's official website and public filings provide comprehensive background.
Is HNGE a long-term quality investment?
From a long-term quality standpoint, HNGE's UQS profile presents a mixed picture. Strong Growth signals are encouraging for long-term potential, but Weak Quality and Moat scores suggest the company still needs to demonstrate durable profitability and competitive defensibility over time. UQS Pro members can view the full pillar breakdown to assess long-term fit.
What is the main competitive advantage of Hinge Health?
Hinge Health's platform targets a high-cost, high-prevalence area of healthcare — musculoskeletal conditions — with a digital-first model that can scale across large employer and health plan populations. However, the UQS Moat pillar currently rates as Weak, indicating this advantage is not yet strongly differentiated from a financial durability standpoint.
What sector does HNGE belong to?
Hinge Health operates in the Healthcare sector, specifically within digital health and health technology. Its platform sits at the intersection of software and clinical care delivery, targeting musculoskeletal conditions for employer-sponsored and health plan populations.
Is HNGE a growth stock or value stock?
Based on its UQS profile, HNGE leans firmly toward the growth category. The Growth pillar is rated Strong, while Valuation is rated Good — suggesting the market prices in meaningful future expansion. It does not exhibit the characteristics typically associated with value investing, such as strong current profitability or a wide moat.
Unlock Full HNGE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown for HNGE
- ✓Access full financial metrics and quality indicators
- ✓Compare HNGE against sector peers side by side
- ✓Track Growth and Risk signals across quarters
- ✓Get the complete analyst-grade view with Pro membership
Pro Analysis
HNGE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 47.7 | 26.9 | 33.0 | 65.9 | 55.2 | 74.8 | +0.6 |
| May 7, 2026 | 47.1 | 26.9 | 33.0 | 65.9 | 57.3 | 68.9 | -0.9 |
| May 3, 2026 | 48.0 | 26.9 | 33.0 | 65.9 | 57.3 | 74.9 | -0.1 |
| May 2, 2026 | 48.1 | 26.9 | 33.0 | 65.9 | 57.3 | 75.8 | 0.0 |
| Apr 26, 2026 | 48.1 | 26.9 | 33.0 | 65.9 | 57.3 | 75.4 | -0.1 |
| Apr 23, 2026 | 48.2 | 26.9 | 33.0 | 65.9 | 57.3 | 76.2 | 0.0 |
| Apr 22, 2026 | 48.2 | 26.9 | 33.0 | 65.9 | 57.3 | 76.1 | -3.2 |
| Apr 19, 2026 | 51.4 | 26.9 | 33.0 | 82.4 | 57.3 | 76.1 | -0.7 |
| Apr 18, 2026 | 52.1 | 26.9 | 33.0 | 82.4 | 57.3 | 80.4 | -0.1 |
| Apr 16, 2026 | 52.2 | 27.3 | 33.0 | 82.4 | 57.3 | 80.4 | -0.2 |
HNGE — Pillar Breakdown
Quality
— 26.7/100 (25%)Hinge Health, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 65.9/100 (20%)Hinge Health, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 55.2/100 (15%)Hinge Health, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 74.2/100 (15%)Hinge Health, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 33/100 (25%)Hinge Health, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HNGE.
Score Composition
Financial Data
More Stock Analysis
How is the HNGE UQS Score Calculated?
The UQS (Unified Quality Score) for Hinge Health, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Hinge Health, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Hinge Health, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.